Mabion (MAB) Stock Overview
A biopharmaceutical company, provides services as a contract development and manufacturing organization in the process development, analytics, and manufacturing of biologic medicines in Poland. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
MAB Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Mabion S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł7.28 |
| 52 Week High | zł10.16 |
| 52 Week Low | zł6.70 |
| Beta | 0.40 |
| 1 Month Change | -0.27% |
| 3 Month Change | -14.95% |
| 1 Year Change | -27.20% |
| 3 Year Change | -55.06% |
| 5 Year Change | -88.20% |
| Change since IPO | -45.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| MAB | PL Biotechs | PL Market | |
|---|---|---|---|
| 7D | -1.6% | 0.07% | 3.1% |
| 1Y | -27.2% | -6.9% | 24.4% |
Return vs Industry: MAB underperformed the Polish Biotechs industry which returned -6.9% over the past year.
Return vs Market: MAB underperformed the Polish Market which returned 24.4% over the past year.
Price Volatility
| MAB volatility | |
|---|---|
| MAB Average Weekly Movement | 5.3% |
| Biotechs Industry Average Movement | 5.3% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in PL Market | 10.5% |
| 10% least volatile stocks in PL Market | 3.0% |
Stable Share Price: MAB has not had significant price volatility in the past 3 months compared to the Polish market.
Volatility Over Time: MAB's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 202 | Krzysztof Kaczmarczyk | www.mabion.eu |
Mabion S.A., a biopharmaceutical company, provides services as a contract development and manufacturing organization in the process development, analytics, and manufacturing of biologic medicines in Poland. It offers drug substance manufacturing, fill and finish, gene to vial end-to-end development, process development, analytics, and banking services. In addition, it offers cell line development, process development, production of a product for preclinical and clinical trials, development and validation of analytical methods, and preparation of the necessary documentation.
Mabion S.A. Fundamentals Summary
| MAB fundamental statistics | |
|---|---|
| Market cap | zł117.66m |
| Earnings (TTM) | -zł57.10m |
| Revenue (TTM) | zł17.61m |
Is MAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MAB income statement (TTM) | |
|---|---|
| Revenue | zł17.61m |
| Cost of Revenue | zł33.44m |
| Gross Profit | -zł15.82m |
| Other Expenses | zł41.27m |
| Earnings | -zł57.10m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Sep 15, 2026
| Earnings per share (EPS) | -3.53 |
| Gross Margin | -89.85% |
| Net Profit Margin | -324.19% |
| Debt/Equity Ratio | 59.6% |
How did MAB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/06 06:23 |
| End of Day Share Price | 2026/07/03 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Mabion S.A. is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Beata Szparaga-Wasniewska | Biuro maklerskie mBanku |
| Kamil Kliszcz | Biuro maklerskie mBanku |
| Pawel Puchalski | Erste Bank Polska S.A. |